Andrea Alms is a venture partner at yet2ventures and leads life science investment analysis and pricing for yet2Ventures. She brings over 15 years of experience sourcing, closing, managing, and exiting equity investments as well as building life science assets and companies. Andrea’s notable life science investments include Adenosine Therapeutics (acquired by Forest Laboratory), Pinnacle Pharmaceuticals (acquired by private equity group), Arbovax, Contravac, Protochips, Bioptigen, and AutoMedx. Andrea also founded and leads BrookDell BioVentures Management, specializing in fund management and intellectual property assets. She is the former fund manager of the Jefferson Corner Group, a member-managed life sciences fund.

Previously, Andrea served as President of Spinner Technologies, Inc., an investment holding and business incubator company specialized in life science companies and developed with the University of Virginia Patent Foundation, a technology transfer office. Her past experience also includes licensing work at the UVA Patent Foundation and research work at Harvard Medical School and Harvard University. 

Andrea holds a B.A. in Economics from Wellesley College, M.S. in Pharmacology from University of Virginia, and M.B.A. from Averett University.neurship (2014). 
Author of “The Manual For Finding A Perfect Mentor For Entrepreneur” (2013). Advisory Board Member at 500 Startups Fund (2013).